1. Home
  2. TBPH vs NQP Comparison

TBPH vs NQP Comparison

Compare TBPH & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • NQP
  • Stock Information
  • Founded
  • TBPH 2013
  • NQP 1990
  • Country
  • TBPH United States
  • NQP United States
  • Employees
  • TBPH N/A
  • NQP N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • NQP Trusts Except Educational Religious and Charitable
  • Sector
  • TBPH Health Care
  • NQP Finance
  • Exchange
  • TBPH Nasdaq
  • NQP Nasdaq
  • Market Cap
  • TBPH 418.7M
  • NQP 438.1M
  • IPO Year
  • TBPH N/A
  • NQP N/A
  • Fundamental
  • Price
  • TBPH $9.69
  • NQP $11.79
  • Analyst Decision
  • TBPH Buy
  • NQP
  • Analyst Count
  • TBPH 4
  • NQP 0
  • Target Price
  • TBPH $13.75
  • NQP N/A
  • AVG Volume (30 Days)
  • TBPH 191.3K
  • NQP 58.4K
  • Earning Date
  • TBPH 11-12-2024
  • NQP 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • NQP 3.21%
  • EPS Growth
  • TBPH N/A
  • NQP N/A
  • EPS
  • TBPH N/A
  • NQP N/A
  • Revenue
  • TBPH $63,192,000.00
  • NQP N/A
  • Revenue This Year
  • TBPH $6.93
  • NQP N/A
  • Revenue Next Year
  • TBPH $45.31
  • NQP N/A
  • P/E Ratio
  • TBPH N/A
  • NQP N/A
  • Revenue Growth
  • TBPH 15.93
  • NQP N/A
  • 52 Week Low
  • TBPH $7.44
  • NQP $9.65
  • 52 Week High
  • TBPH $11.71
  • NQP $11.89
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 70.66
  • NQP 38.26
  • Support Level
  • TBPH $9.38
  • NQP $11.67
  • Resistance Level
  • TBPH $10.10
  • NQP $11.80
  • Average True Range (ATR)
  • TBPH 0.32
  • NQP 0.12
  • MACD
  • TBPH 0.11
  • NQP 0.02
  • Stochastic Oscillator
  • TBPH 83.26
  • NQP 76.81

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About NQP Nuveen Pennsylvania Quality Municipal Income Fund

Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: